Clene is a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases with first-in-class nanotherapeutics. Their science harnesses the extraordinary properties of elemental nanocrystals for therapeutic use.
Clene’s nanotherapeutics target cellular energy impairments that are common to many diseases. This novel approach has allowed Clene to explore broad applications of their drugs across therapeutic areas.
The Clene team believes in applying innovations to therapeutic challenges that currently have no effective solutions. With the right mix of experience, expertise, and creativity, Clene is changing the landscape of clinical development.